Article
A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice.
Biological chemistry - 27 Nov 2018
Essalmani Rachid, Weider Elodie, Marcinkiewicz Jadwiga, Chamberland Ann, Susan-Resiga Delia, Roubtsova Anna, Seidah Nabil G, Prat Annik
Abstract excerpt
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that binds and escorts the low density lipoprotein receptor (LDLR) into the lysosomal degradation pathway. Prescribed monoclonal antibodies (mAbs) against PCSK9 prevent its binding to the LDLR, and result in ~60% lower LDL cholesterol (LDLc) levels. Although efficient, mAbs are expensive. Hence other PCSK9 inhibitors are needed. For...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.